Many studies have demonstrated significant effects such as specific in vivo therapeutic efficacy against prostate cancer in a PSMA-expressing LNCaP cell xenograft mouse model [78,79,80,81]. The gene discussed is FOLH1; the disease is prostate carcinoma.